{
  "title": "Patient-Reported Symptom Assessment and Early Chemotherapy Discontinuation in ... - medRxiv",
  "url": "https://www.medrxiv.org/content/10.1101/2025.10.07.25337194v1",
  "summary": [
    {
      "type": "bullet",
      "text": "**KEY FINDING**: 67% completion reduced early discontinuation risk by 30%, demonstrating PRO's clinical validity."
    },
    {
      "type": "bullet",
      "text": "**TACTICAL WIN [SHIP NOW]**: Deploy day-3 auto-reminders to improve completion rates and patient outcomes."
    },
    {
      "type": "bullet",
      "text": "**MARKET SIGNAL [ðŸŸ¡ NOTABLE]**: Rising regulatory pressure for PRO data in trials could accelerate ePRO adoption."
    },
    {
      "type": "bullet",
      "text": "**CONCERN**: Self-selection bias may limit generalizability of findings to all GI cancer populations."
    }
  ],
  "model": "granite4:tiny-h"
}